Navigation Links
Athera Biotechnology Founder Johan Frostegard and His Colleagues Win NACB Distinguished Abstract Award at AACC 2008
Date:7/29/2008

WASHINGTON DC, July 29 /PRNewswire/ -- Athera Biotechnology announced the Award from NACB (National Academy of Clinical Biochemistry) for Distinguished Abstracts at the annual AACC (American Association of Clinical Chemistry) meeting in Washinton DC was awarded to Athera Biotechnology founder Johan Frostegard and his colleagues. The abstract was one of 26 selected for the award, among over 700 accepted abstracts. Winners will be honored at NACB Award luncheon held at the AACC meeting on July 30.

Frostegard's abstract describes a study where low levels of antibodies against phosphorylcholine (anti-PC) were measured using an enzyme linked immunoassay (ELISA) by CVDefine(TM), a new kit developed by Athera. The findings indicate that low levels of IgM anti-PC are associated with an increased risk of cardiovascular disease (CVD) in a population. Frostegard and colleagues conclude that low levels of anti-PC could be a novel risk marker for CVD and ischemic stroke, especially in men.

Athera Biotechnologies AB develops novel products for risk assessment and treatment of CVD. The company was founded in 2002 to exploit findings made by Professors Johan Frostegard and Ulf de Faire on the critical role of phospholipid antibodies (aPL) in the inflammatory process of cardiovascular disease. Athera is based in Karolinska Institutet Science Park in Stockholm and main investors include Karolinska Development and Baltic Sea Foundation. Athera is also a major partner in the highly ranked EU-project CVDIMMUNE lead by Karolinska Institutet. The project involves 10 academic and industrial partners, including Phadia GmbH, Johannes Gutenberg-University Mainz and Leiden University Medical Center.


'/>"/>
SOURCE Athera Biotechnologies AB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Pennsylvania Governor Rendell Says State Number 1 in New Biotechnology Study
2. WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology
3. Yongye Biotechnology International, Inc. Appoints New Independent Auditor
4. Genetic Engineering & Biotechnology News reports on novel hit-to-lead drug discovery
5. Dietitian Mary Lee Chin Comments on Proven Value and Safety of Food Biotechnology in New Online Video
6. N.C. Biotechnology Center Launches Industrial Fellowship Program
7. Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs
8. In a Year of Unprecedented Growth for Biotechnology Innovation, Targeted Therapies Gain Most Significant Traction, According to New Deloitte Study
9. Pharsight to Present on Literature-Based Disease Modeling Approaches at AAPS National Biotechnology Conference
10. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
11. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... While ... machines such as the Cary 5000 and the 6000i models are higher end machines ... is the height of the spectrophotometer’s light beam from the bottom of the cuvette ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
Breaking Biology Technology:
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
(Date:6/2/2016)... -- Perimeter Surveillance & Detection Systems, Biometrics ... Support & Other Service  The latest report ... analysis of the global Border Security market . ... $17.98 billion in 2016. Now: In November ... software and hardware technologies for advanced video surveillance. ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
Breaking Biology News(10 mins):